PubMed Health⌕ Search

Biomedical subjects

X Filella

Publications and source records attributed to X Filella.

105 records · Page 6Linked to original sources
PubMedDate not supplied

Tumor markers in patients with chronic renal failure.

In order to evaluate the specificity of tumor markers in chronic renal failure, we have determined serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA 19.9), carbohydrate antigen 50 (CA 50), alphafetoprotein (AFP), neuron-specific enolase (NSE), prostatic acid phosphatase (PAP), prostatic specific antigen (PSA), squamous cell carcinoma antigen (SCC), carbohydrate antigen 15.3 (CA 15.3) and carbohydrate antigen 125 (CA 125) in 30 patients with chronic renal failure and in 36 hemodialyzed patients without clinical evidence of neoplasia. CEA, CA 50, NSE and SCC frequently show increased serum levels, suggesting a renal metabolism, while others remain, generally, within the normal levels.

Acid Phosphatase↗
PubMedDate not supplied

Significance of CA72.4 in patients with colorectal cancer. Comparison with CEA and CA19.9.

CA72.4 is a new tumor-associated antigen identified by monoclonal antibodies cc49 and B72.3. Serum levels of CA72.4 were measured in patients with benign and malignant diseases. The cut-off used was 4 U/mL. CA72.4 is a highly specific marker since only 3% of 162 patients with benign diseases had elevated levels of antigen. Forty-four percent of 89 patients with colorectal cancer had elevated CA72.4 levels. Compared with CEA and CA19.9, we have found that CEA (75%) is the most sensitive marker (p less than 0.001). The simultaneous use of two or three markers did not further contribute to the evaluation of patients with colorectal cancer.

Antigens, Tumor-Associated, Carbohydrate↗
PubMedDate not supplied

MCA in patients with breast cancer: correlation with CEA and CA15-3.

MCA serum levels were determined in 27 healthy subjects, 136 with benign pathology (42 breast) and in 289 patients with cancer (247 active). The last group includes 223 patients with breast cancer (96 without metastases, 89 with metastases and 38 no-evidence of disease). CEA and CA15-3 serum levels were determined in all the patients with breast diseases. The mean levels of MCA were 4.7 + 2.4 U/ml in the control group, considering less than 11 U/ml as normal. MCA values were abnormal in 15.4% of patients with benign pathology, mainly in those with liver cirrhosis (8/20) and lung diseases (4/20). In the majority of these cases, the rise was only moderate, lower than 15 U/ml in 97.5% of patients. In malignant diseases, important increments were found in breast cancer (19.8% Mo, 77.5% M1) and ovarian cancer stages III-IV (44.4%). When we compared MCA serum levels with CA15-3 and CEA in breast pathology, a similar specificity was observed: 92.3%, 92.3% and 100% in cases with benign pathology and 92.1%, 94.7%, and 97.4% in NED patients, respectively. MCA and CA15-3 sensitivity was similar in breast cancer without metastases (19.8%) and lower for CEA (16.7%). In patients with breast cancer without metastases, we found a relation between positivity of these tumor markers and prognostic factors (tumor size, nodal involvement). The disease free interval in patients with locoregional breast cancer was shorter in cases with abnormal presurgical levels of some of the tumor markers, but only the difference from MCA was significant (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

Antigens, Neoplasm↗
PubMedDate not supplied

A new immunonephelometric method for amniotic fluid alpha-fetoprotein measurement.

We have evaluated the analytic performance of a new immunonephelometric method developed for the measurement of amniotic fluid alpha-fetoprotein (AF-AFP) and compared it with the classic immunoradiometric method used up to now. Intrassay precision, evaluated for three AF-AFP levels, was good and Interassay imprecision shows higher coefficients of variation (CVs) especially for medium and high AF-AFP levels. Linearity was demonstrated for level higher than 300,000 ng/ml and no hook effects was observed. Comparison with an IRMA method gave the following regression equation: y = 3050 + 0.52X (r = 0.76, p less than 0.001, n = 36).

Amniotic Fluid↗
PubMedDate not supplied

Alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma.

Increased AFP levels in patients with hepatocellular carcinoma are mainly related to tumor size and in a lesser degree, to AST levels. Abnormal and/or diagnostic AFP levels will be observed in a reduced proportion of patients with small HCC (less than 5 cm). Therefore, AFP measurement is of little value in the early detection of HCC.

Aged↗
PubMedDate not supplied

Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.

TPS and SCC serum levels were evaluated in 113 patients with primary tumors, 19 with relapse and 59 with no evidence of disease after radical treatment. Abnormal serum levels were found in 37% and 33% of patients with primary untreated tumors and in 53% and 59% of patients with relapse, respectively, using 100 U/L and 2.5 ng/ml as the upper limit of normality for TPS and SCC, respectively. Either tumor marker was abnormal in 57.5% of primary tumors and in 74% of patients with relapse. TPS and SCC serum levels were related to nodal involvement, with significantly higher levels in patients with nodal invasion (p < 0.02 and p 0.001, respectively). No relationship was found between tumor size, age or histological grade and SCC or TPS values. Pretreatment TPS and SCC serum levels had prognostic interest in patients with locoregional tumors, with a significantly shorter disease-free interval (DFI) in patients with abnormal values (p < 0.01 and p < 0.02, respectively). When tumor marker levels and nodes were simultaneously evaluated, a trend toward shorter DFI in patients with abnormal serum concentrations was found, with no statistical significance. By contrast, TPS and SCC were useful in prognosis in node-negative patients (p < 0.02 and p < 0.001, respectively). Likewise, using both TAAs simultaneously, it is possible to increase prognostic information. Patients with TPS and/or SCC abnormal levels had a significantly lower DFI than those patients with normal values, in both node positive and negative patients (P < 0.01). In summary, TPS and SCC are useful TAAs in patients with head and neck malignancies. Likewise, with the simultaneous use of SCC and TPS, the TAA utility in this malignancy increases in the prognosis as well as disease follow-up.

Antigens, Neoplasm↗
PubMedDate not supplied

CEA as a prognostic factor in colorectal cancer.

We have measured serum CEA levels in 207 patients with colorectal cancer. CEA sensitivity was related to tumor stage in tumors located in the right colon, but not in tumors located in the left colon or the rectum. CEA had prognostic value in patients with tumors located in the right colon (p < 0.001) but not in the left colon or the rectum. However, CEA did not have prognostic value independent of Dukes stage even in tumors in the right colon. Our results underline the different sensitivities and prognostic values for primary tumors in the left and right colorectal regions.

Carcinoembryonic Antigen↗
PubMedDate not supplied

TPA prognostic value in superficial bladder cancer.

We determined the levels of TPA in 133 patients with superficial bladder cancer. 79 cases were Ta stages, and 54 cases T1 stages. 53 of the tumors were well differentiated (I), 65 moderately differentiated (II) and 15 undifferentiated (III). The average follow-up time of these patients was 8.3 months; the standard deviation being 5.2 months (median value 7 months). In 43 cases a relapse of the tumor was observed. We detected high TPA levels in 25% of the patients, without observing meaningful differences in tumor invasion or in its differentiation degree. The usefulness of the TPA, the degree of tumor invasion, and the degree of cell differentiation were evaluated by means of single-variate and multivariate analysis in order to forecast tumor relapse. Only the TPA had a prognostic value, the relative risk of developing relapse being 2.03 times higher in patients with high TPA than patients with normal TPA.

Aged↗
PubMedDate not supplied

C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis.

C-erbB-2 serum levels were studied in the sera of 50 healthy subjects, 56 patients with benign breast diseases and 412 patients with breast cancer. Using 15 U/ml as the cut-off, no healthy subjects, patients with benign disease and only 2.4% of patients with no-evidence of disease had serum levels higher than this cut-off point. Abnormal c-erbB-2 levels were found in 9.2% of the patients with locoregional breast carcinoma and in 45.4% of those with advanced disease. C-erbB-2 serum levels in patients with locoregional breast cancer were not related to tumor size or nodal involvement. By contrast, significantly higher c-erbB-2 serum levels were found in ER- or PgR- tumors than in those ER+ or PgR+ tumors, in both locoregional or metastatic tumors. The correlation between serum and tissue levels of C-erbB-2 was studied in the tumors of 161 patients. Significantly higher c-erbB-2 serum levels were found in patients with overexpression in tissue by immunohistochemistry, in both locoregional and advanced disease (p = 0.0001). In patients with C-erbB-2 overexpression in tissue, c-erbB-2 serum levels were related to tumor size and nodes, with higher values in tumors greater than 5 cm or in those with more than 3 nodes involved. When the prognostic value of this oncoprotein was evaluated, patients with abnormally high presurgical c-erbB-2 had a worse prognosis than those patients with normal values, in both node-negative and node-positive patients. Serum concentrations in patients with advanced disease, were related to the site of recurrence with significantly higher values in patients with metastases (mainly in those with liver metastases) than in those with locoregional recurrence. In summary, c-erbB-2 serum level seem to be a useful tumor marker in the prognosis of patients with breast cancer.

Breast Neoplasms↗
PubMedDate not supplied

Multicentre clinical evaluation of the COBAS CORE CEA, CA 125 II and PSA tumor marker assays.

The aim of our study was to evaluate the clinical usefulness of the tumor markers CEA, CA 125 and PSA using the COBAS CORE system from Roche Diagnostic Systems. Our results demonstrate that determination of these markers on the COBAS CORE immunoassay analyser provides the performance required for routine use in clinical practice. The results obtained in this clinical trial validate the correlation with disease extension, a characteristic that defines and determines the clinical utility of the tumor markers. We also conclude that learning to operate the COBAS CORE system is simple, as is management of the system through the user-friendly software.

Adolescent↗
PubMedDate not supplied

Detection of occult liver metastases in colorectal cancer by measurement of biliary carcinoembryonic antigen.

About a 20-25% of the patients at diagnosis of colorectal carcinoma present with occult liver metastases. The aim of this work was to determine the prognostic significance of CEA bile level for the early detection of occult metastases. We determined the CEA blood level and the CEA bile level in 182 patients with colorectal carcinoma (3 Dukes' stage A, 86 Dukes' stage B, 53 Dukes' stage C, and 40 patients with liver metastases) and also in 42 patients with simple cholelithiasis, as the control group. In the patients with cholelithiasis, the mean values of CEA serum and bile levels were normal. In patients with colorectal carcinomas the CEA serum levels ranged from 3 to 110 ng/ml, and the CEA bile level from 3 to 226 ng/ml. Patients with liver metastases, had a mean CEA serum level of 193 ng/ml, while CEA bile level was 1,225 ng/ml. In conclusion, our results suggest that the determination of CEA bile is highly useful in the diagnosis of occult liver metastases.

Bile↗
PubMedDate not supplied

p53 oncoprotein as a prognostic indicator in patients with breast cancer.

UNLABELLED: p53 is a tumor suppressor gene located on the human chromosome 17 that is thought to regulate (suppress) the proliferation of normal cells. The mutant protein accumulates in the nuclei of tumor cells that may then have a proliferative advantage over normal cells. The purpose of this study was to investigate the relationship between levels of mutant p53 expression and the clinical outcome of patients with node-positive and node-negative breast cancer. Expression of mutant p53 was evaluated in 655 human breast carcinomas (349 node-positive and 306 node-negative patients) with long-term clinical follow-up by immunohistochemistry in sections from paraffin embedded tumors. RESULTS: Immunoreactivity was found in 37.3% of breast tumors. There was no significant correlation between the expression of p53 and tumor size, nodal involvement, age or histological type. However, p53 overexpression was clearly related to histological grade and steroid receptors, with a trend to higher overexpression in ER-tumors or in those with a high histological grade (p < 0.01). On univariate analysis positive tumors were associated with reduced DFS in the total group (p < 0.001) as well as in node-positive patients (p < 0.05) and in node-negative patients (p < 0.01). In conclusion, these results suggest that the immunoreactivity of p53 may be a biologic marker of prognostic significance in both node-positive and node-negative patients.

Biomarkers, Tumor↗
PubMedDate not supplied

Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report.

BACKGROUND: The significance of tumor markers in lung cancer is not well established. PATIENTS AND METHODS: We analyzed level of serum markers as prognostic factor of response and survival in 46 evaluable patients with locally advanced or metastasic non small cell lung cancer. All patients were treated with cisplatin 120 mg/m2 or carboplatin 400 mg/m2 day 1, plus etoposide 80 mg/m2 days 1 to 3. RESULTS: Partial response was obtained in 11 patients (24%), stabilization in 18 and progression in 17. Tumor marker sensitivities were: CEA 37%, CA 125 54.5%, SCC 17.5%, NSE 30.5%, and CYFRA 52%. Higher levels of CEA and NSE correlated with more probability of response (p < 0.001 and p = 0.002). The survival probability of patients with normal pretreatment levels of NSE was significantly better than those with NSE over normal level (15.2 vs 7.2 months) p = 0.02. In patients who achieved partial response, CEA, CA 125 and CYFRA levels decreased significantly with respect to the pretreatment values. CONCLUSIONS: Patients with high CEA and NSE serum level have an increased probability of response than patients with low initial levels; however, patients with high initial level of NSE have poor survival. The decrease in CEA, CA 125 and CYFRA values at the moment of response evaluation could help in response assessment.

Adult↗
PubMedDate not supplied

Lack of correlation between tumor markers (CA 125 and SCC) and systemic lupus erythematosus activity.

BACKGROUND: Recently, tumor markers (CA 125 and SCC) have been suggested as possible activity markers of systemic lupus erythematosus (SLE), but study results have been contradictory. OBJECTIVE: The aim of this study was to evaluate the possible relationship between CA 125 and SCC serum levels and SLE activity. PATIENTS AND METHODS: Serum levels of CA 125 from 59 patients and levels of SCC from 53 patients with SLE were analyzed. Both tumor markers were determined by ELISA, considering 35 U/ml (CA 125) and 2.5 ng/ml (SCC) respectively as the upper limit of normality. The serum levels of these tumor markers were correlated with the SLE disease activity index (SLEDAI). RESULTS: The CA 125 concentrations in active SLE (mean 13.8 + 15.3) were similar to those in inactive patients (mean 13.1 + 11.7 U/ml). Significantly high CA 125 serum levels were found only in SLE patients with nephrotic syndrome (p = 0.001). No significant differences were found in SCC serum levels in SLE patients with (mean 0.9 +/- 0.8 ng/ml) or without activity (mean 1.1 +/- 1.3 ng/ml). Likewise, no relationship between SCC serum levels and parameters related to SLE activity were found, excluding slight increases associated with renal failure. CONCLUSIONS: The correlation that some authors have found between elevated serum levels of CA 125 and SLE activity is only associated with the presence of nephrotic syndrome. Likewise, SCC is not related with SLE activity and the increases found may be due to renal failure.

Antigens, Neoplasm↗